Agomab Therapeutics NV, headquartered in Ghent, Belgium, is a clinical-stage biopharmaceutical company dedicated to pioneering treatments for fibro-stenotic and regenerative diseases. Established in 2017, the company leverages its deep understanding of growth factor biology to develop a pipeline of small molecules and antibodies designed to modulate pathways that drive fibrosis and tissue repair. Agomab’s therapeutic strategy focuses on two primary pathways: the Transforming Growth Factor beta (TGF-β) pathway and the Hepatocyte Growth Factor (HGF) pathway. Their lead clinical candidate, AGMB-129, is a gut-restricted, small-molecule inhibitor of ALK5 (TGF-β receptor 1) currently being evaluated for the treatment of fibrostenotic Crohn’s disease. By inhibiting ALK5 locally in the gastrointestinal tract, the company aims to prevent and reverse the fibrotic complications that often lead to surgery in Crohn's patients. In addition to its gastrointestinal programs, Agomab is developing AGMB-447, an inhaled ALK5 inhibitor for Idiopathic Pulmonary Fibrosis (IPF), and AGMB-101, a MET-agonistic antibody designed for regenerative applications in organ failure. The company’s approach combines precision medicinal chemistry with a focus on high unmet medical needs in chronic inflammatory conditions. Led by CEO Tim Knotnerus, Agomab has secured significant backing from prominent life sciences investors and successfully transitioned to a public company on the NASDAQ exchange to fund its expanding clinical trials and research initiatives.
No data found.